Company Encyclopedia
View More
name
NO.1 PHARMACY
600833.SH
Shanghai No.1 Pharmacy Co.,Ltd., together with its subsidiaries, engages in the retail and wholesale of pharmaceutical products in China. It sells food, medical equipment, health convenience products, and other commodities. The company serves terminal medical institutions, pharmacies, commodity distribution companies, and company franchise stores companies. Shanghai No.
90.45 B
600833.SHMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
B
Drug RetailIndustry
Industry Ranking3/9
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreC
    • ROE6.05%C
    • Profit Margin3.31%C
    • Gross Margin15.88%D
  • Growth ScoreC
    • Revenue YoY12.56%B
    • Net Profit YoY-61.47%D
    • Total Assets YoY5.27%B
    • Net Assets YoY3.69%C
  • Cash ScoreB
    • Cash Flow Margin3021.98%A
    • OCF YoY12.56%B
  • Operating ScoreA
    • Turnover1.05A
  • Debt ScoreC
    • Gearing Ratio42.37%C

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    NO.1 PHARMACY released its performance for the first three quarters, with a net profit attributable to the parent company of 53.27 million yuan, a year-on-year decrease of 63.84%

    According to the Zhitong Finance APP, NO.1 PHARMACY disclosed its third-quarter report for 2025. The company achieved revenue of 1.539 billion yuan in the first three quarters, a year-on-year increase of 12.43%; the net profit attributable to the parent company was 53.27 million yuan, a year-on-year decrease of 63.84%; the net profit excluding non-recurring gains and losses was 9.64 million yuan, a year-on-year increase of 23.36%; the basic earnings per share were 0.2388 yuan

    Zhitong·
    SH
    600833
    -0.14%
    Zhitong·
    SH
    600833
    -0.14%

    NO.1 PHARMACY released its performance for the first half of the year, with a net profit attributable to the parent company of 14.0242 million yuan, a decrease of 89.19%

    NO.1 PHARMACY released its 2025 semi-annual report, with operating revenue of 997 million yuan, a year-on-year increase of 11.58%. The net profit attributable to the parent company was 14.0242 million yuan, a year-on-year decrease of 89.19%. The net profit after deducting non-recurring gains and losses was 9.012 million yuan, a year-on-year increase of 24.58%. The basic earnings per share were 0.0629 yuan. The company achieved operational returns through the expansion of innovative businesses and cost reduction and efficiency improvement

    Zhitong·
    SH
    600833
    -0.14%
    Zhitong·
    SH
    600833
    -0.14%

    NO.1 PHARMACY issues a profit warning, expecting a net profit attributable to the parent company of 12.6 million to 15.8 million yuan for the half-year, a year-on-year decrease of 87.83% to 90.29%

    According to the Zhitong Finance APP, NO.1 PHARMACY announced that the company expects to achieve a net profit attributable to the owners of the parent company of 12.6 million to 15.8 million yuan for the first half of 2025, a year-on-year decrease of 87.83% to 90.29% compared to the same period last year. The decline in net profit attributable to the owners of the parent company during this period is mainly due to the existence of housing expropriation compensation in the same period last year

    Zhitong·
    SH
    600833
    -0.14%
    Zhitong·
    SH
    600833
    -0.14%

    The pharmaceutical commercial sector has seen a short-term decline, with NO.1 PHARMACY dropping over 6%

    The pharmaceutical commercial sector has declined in the short term, with NO.1 PHARMACY dropping over 6%, and YIXINTANG, ZHEJIANG ZHENYUAN, SYPM, Runda Medical, and others following suit

    Zhitong·
    SZ
    000705
    +0.90%
    SZ
    301017
    +4.47%
    SH
    603108
    +1.42%
    Zhitong·
    SZ
    000705
    +0.90%
    SZ
    301017
    +4.47%
    SH
    603108
    +1.42%

    NO.1 PHARMACY released its first-quarter performance, with a net profit attributable to the parent company of 4.7391 million yuan, a year-on-year decrease of 86.86%

    NO.1 PHARMACY released its Q1 2025 performance report, with operating revenue of 504 million yuan, a year-on-year increase of 9.07%. However, the net profit attributable to shareholders of the listed company was 4.7391 million yuan, a year-on-year decrease of 86.86%. The net profit after deducting non-recurring gains and losses was 4.4955 million yuan, a year-on-year increase of 1.13%. The basic earnings per share were 0.0212 yuan/share

    Zhitong·
    SH
    600833
    -0.14%
    Zhitong·
    SH
    600833
    -0.14%
    © 2025 Longbridge｜Disclaimer